MANKIND PHARMA LTD’s Post

Its finally announced ! The return of the spurned Indian strategic eh? PE Advent sells Bharat Serums & Vaccines to Mankind Pharma ( which lost the race earlier for Apax Partners backed Healthium Medtech to KKR) in a mega deal with EV of Rs 13,630 crore! Consequently , the winning suitor says it is now a market leader in Indian women’s health & fertility segment. Remember , the drugmaker listed on the bourses last year and galvanized the Indian IPO market .. Here is the detailed story with perspectives from seller, buyer and the target -

3-REASONS why MANKIND PHARMA LTD acquired Bharat Serums and Vaccines Limited (BSV) for ₹13,630Cr, giving Advent International a 2.8X exit in just 4 years? 🚀 Mankind's journey from ₹5Cr in 1995 to ₹10,000Cr in 2024 is impressive, but the goal is now ₹50,000Cr in the next decade! To get there, they need higher margins and a stronger foothold in the super-specialty market. This acquisition is their ticket to the big leagues, expanding into Women's Health, ART, Critical Care, and Emergency Medicine. With BSV's R&D across India, Germany, Ukraine, Philippines & Malaysia, the future looks promising. What do you think of this Bharat-Mankind match? 👀 Follow AGENDA+HEALTH #healthtech #pharma #India #acquisition #growth #strategy #MankindPharma #BharatSerums

Partnership will boost the vaccine Production.

Mankind Pharma is acquiring biotech company BSV Group, (formerly Bharat Serum & Vaccines) from PE firm Advent International for an enterprise value of around Rs 13,630 crore, subject to closing related adjustments. TIMES OF INDIA: The deal marks a significant leap for Mankind Pharma, positioning it as a market leader in India's women's health and fertility drug market, alongside access to other high-entry barrier products in critical care, with established complex R&D tech platforms. It will potentially establish Mankind as the number one player in the Rs 11,000 cr gynaecology market, with a 13% share. At present, Mankind is ranked third, and has a 7% market share, while BSV 6%. Source: Times of India

🚀 Mankind Pharma's Strategic Leap Forward Mankind Pharma Ltd has entered into a definitive agreement to acquire a 100% stake in Bharat Serums and Vaccines Ltd (BSV) from Advent International for an enterprise value of approximately ₹13,630 crore, subject to closing-related adjustments. This acquisition represents a significant milestone for Mankind Pharma, solidifying its leadership in the Indian women’s health and fertility drug market. BSV’s robust portfolio, which spans the entire lifecycle of women’s health—from fertility to post-pregnancy—perfectly aligns with our strategic vision to expand into high entry barrier markets. BSV's Specialty R&D Tech Platforms, with a complex portfolio across women’s health, fertility, critical care, and the immunoglobulin segment, further strengthen our position in the industry. With reported revenues of ₹1,723 crore in FY24, delivering 20% year-on-year growth and adjusted EBITDA margins of 28%, BSV has shown remarkable performance, growing at a 21% revenue CAGR over the last three years. This strategic move enables us to expand our footprint and continue delivering innovative, high-quality healthcare solutions to patients across India. #MankindPharma #HealthcareLeadership #Pharmaceuticals #Acquisition #WomensHealth #Fertility #CriticalCare #Innovation #BharatSerumsAndVaccines Karan Chechi | Alwin Samuel | Shaurya Singh | TechSci Research | MANKIND PHARMA LTD | Bharat Serums and Vaccines Limited

There aren’t any shortcuts to success says common wisdom however don’t we love shortcuts? #health & #fitness work on a fundamental rule: don’t overestimate the short-term nor underestimate the long-term. No shortcuts However #semaglutide medications are upending some established ground rules by reinventing anti-obesity drug market, which is estimated to be $40B rising to $100B by end of the decade From Novo Nordisk becoming the most valuable company in EU & preventing recession in Denmark to an equally statospheric rise in market cap of Eli Lilly, what’s clear is that for a foreseeable future, demand far outstrips supply when it comes to #WeightLossDrugs Can this magic pill create shortcuts that work? Thoughts? https://lnkd.in/gPipVZ9U

🚀 Excited to share the inspiring journey of Mankind Pharmaceuticals, India's second-largest pharmaceutical company! 🌟 Founded in 1995 by R.C. Juneja and Rajeev Juneja, Mankind Pharmaceuticals has grown exponentially, thanks to its vision of providing affordable healthcare to all, especially in rural and semi-urban areas. Key Highlights: Vast Product Range: From prescription medicines to OTC products and veterinary medicines, Mankind covers various therapeutic areas. Popular Brands: Manforce condoms and Prega News pregnancy test kits have become household names in India. Global Presence: Expanding international footprints with exports to multiple countries. Commitment to R&D: State-of-the-art R&D centers and manufacturing facilities ensure continuous innovation. CSR Initiatives: Actively involved in healthcare, education, and community welfare. Proud to see an Indian company making such a significant impact globally while staying true to its mission of affordable healthcare. 🌍💊 #Pharmaceuticals #Healthcare #Innovation #CSR #India #MankindPharma

Sanofi India Limited, along with Sanofi Health care India Private Limited, has joined hands with Cipla Limited to announce an exclusive distribution partnership aimed at expanding the reach of Sanofi India's #Central Nervous System (CNS) product range across #India. Under this collaboration, Cipla will undertake the distribution and promotion of Sanofi India's six #CNSbrands, including the renowned Frisium®, a leading name in the anti-epileptic #medicationcategory. While Sanofi India will retain ownership and continue to manage the manufacturing and importing processes of its complete #CNSproduct line, Cipla will leverage its extensive network and robust #marketing infrastructure to enhance accessibility to these treatments across the country. Rodolfo H., Managing Director of Sanofi India Limited, expressed confidence in the partnership, stating, "Sanofi India's CNS products are esteemed leaders in their respective categories, significantly impacting the lives of patients in urban areas. Partnering with Cipla will enable us to extend the reach of this portfolio to healthcare professionals and patients nationwide." Achin Gupta, CEO of One India Business at Cipla Limited, emphasized the company's commitment to improving access to high-quality treatments, particularly in challenging therapeutic areas like CNS. He remarked, "Enhancing access to highly efficacious and quality therapeutic solutions in CNS aligns with our purpose of 'Caring for Life'. This collaboration with Sanofi India represents a significant step forward in addressing the unmet needs of patients in this critical medical domain." Sanofi India remains steadfast in its dedication to accelerating innovation and expanding its robust pipeline across various therapeutic areas, including Diabetes, Transplants, Rare Diseases, Consumer Healthcare, and Vaccines. This strategic partnership with Cipla marks a significant milestone in its mission to enhance patient care and improve healthcare accessibility across India. https://lnkd.in/gDkVBrc8 #News #Medlr #Healthnews #Healthcare #Health

On July 25, 2024, MANKIND PHARMA LTD achieved a significant industry milestone by acquiring Bharat Serums and Vaccines Limited (BSV) for ₹13,630 crore. This acquisition marks a major step in Mankind’s global expansion into biopharmaceuticals and critical care. Key takeaways include: • 𝗠𝗮𝗿𝗸𝗲𝘁 𝗟𝗲𝗮𝗱𝗲𝗿: Mankind becomes a leader in India's women’s health and fertility market. • 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗚𝗿𝗼𝘄𝘁𝗵: BSV’s FY24 revenue was ₹1,723 crore with 20% growth and a 28% EBITDA margin. • 𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 𝗼𝗳 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼: BSV adds fertility, post-pregnancy, and critical care products to Mankind’s lineup. • 𝗦𝘆𝗻𝗲𝗿𝗴𝗶𝘀𝘁𝗶𝗰 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀: Integration of BSV’s R&D and 2,500 employees will enhance Mankind’s offerings and market reach. For more latest industry news and updates, visit the 'Industry News' section on our website at Markets & Data: https://lnkd.in/dnSihCsG #industry #news #BSV #healthcarer #Mankind #acquisition #latest #development #pharmaceutical #health